I feel quite independent now : The life of Mary Greenhow Lee

This biography of Mary Greenhow Lee of Virginia examines life in the nineteenth century. Born in Richmond in 1819, Lee married a lawyer of modest means in Winchester, became widowed thirteen years later, lived through the Civil War in a border town coveted by both armies, then finally settled in Baltimore where she ran a boarding house to make a living until her death in 1907. The purpose of this study is to use a single personality from the past to examine life in the nineteenth-century South from a woman\u27s perspective, using historic events as a backdrop to the narrative.;Mary Greenhow Lee\u27s life illustrates the role of women in nineteenth-century southern society. Her story is also useful for examining the frustrations and triumphs of women who lived in areas of conflict during the Civil War. Additionally, there are two threads that run throughout this biography. One is the way Lee\u27s character aided her in making decisions and overcoming difficult situations. Mary Greenhow Lee\u27s intelligence, wit, and defiant spirit drove her own history, and explains how she made the myriad choices confronting her through her life. The other element that ties this biography together is Lee\u27s sense of social place, studying the very intimate workings of a network of southerners who felt comfortable with and relied upon each other. The war led many of them, however, to create alliances with other classes for mutual support. Finally, Lee\u27s Civil War journal demands a thematic approach to the war years, examining Mary Greenhow Lee\u27s identity as a southern national, civilian reactions to life in a war zone, and the ways that Lee used her role as a woman to support Confederate soldiers while she manipulated and opposed Union occupiers in Winchester

Women Making War: Female Confederate Prisoners and Union Military Justice

Thomas F. Curran shows that not only did southern white women participate in politics while aiding and abetting Confederate soldiers, bushwhackers, and guerrillas, possibly as many as 200 of such women were arrested and imprisoned for their efforts to help the Confederacy

Modulation of Genetic Associations with Serum Urate Levels by Body-Mass-Index in Humans

We tested for interactions between body mass index (BMI) and common genetic variants affecting serum urate levels, genome-wide, in up to 42569 participants. Both stratified genome-wide association (GWAS) analyses, in lean, overweight and obese individuals, and regression-type analyses in a non BMI-stratified overall sample were performed. The former did not uncover any novel locus with a major main effect, but supported modulation of effects for some known and potentially new urate loci. The latter highlighted a SNP at RBFOX3 reaching genome-wide significant level (effect size 0.014, 95% CI 0.008-0.02, P-inter= 2.6 x 10(-8)). Two top loci in interaction term analyses, RBFOX3 and ERO1LB-EDAR-ADD, also displayed suggestive differences in main effect size between the lean and obese strata. All top ranking loci for urate effect differences between BMI categories were novel and most had small magnitude but opposite direction effects between strata. They include the locus RBMS1-TANK (men, Pdifflean-overweight= 4.7 x 10(-8)), a region that has been associated with several obesity related traits, and TSPYL5 (men, Pdifflean-overweight= 9.1 x 10(-8)), regulating adipocytes-produced estradiol. The top-ranking known urate loci was ABCG2, the strongest known gout risk locus, with an effect halved in obese compared to lean men (Pdifflean-obese= 2 x 10(-4)). Finally, pathway analysis suggested a role for N-glycan biosynthesis as a prominent urate-associated pathway in the lean stratum. These results illustrate a potentially powerful way to monitor changes occurring in obesogenic environment.Peer reviewe

Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study

Introduction: The multiorgan impact of moderate to severe coronavirus infections in the post-acute phase is still poorly understood. We aimed to evaluate the excess burden of multiorgan abnormalities after hospitalisation with COVID-19, evaluate their determinants, and explore associations with patient-related outcome measures. Methods: In a prospective, UK-wide, multicentre MRI follow-up study (C-MORE), adults (aged ≥18 years) discharged from hospital following COVID-19 who were included in Tier 2 of the Post-hospitalisation COVID-19 study (PHOSP-COVID) and contemporary controls with no evidence of previous COVID-19 (SARS-CoV-2 nucleocapsid antibody negative) underwent multiorgan MRI (lungs, heart, brain, liver, and kidneys) with quantitative and qualitative assessment of images and clinical adjudication when relevant. Individuals with end-stage renal failure or contraindications to MRI were excluded. Participants also underwent detailed recording of symptoms, and physiological and biochemical tests. The primary outcome was the excess burden of multiorgan abnormalities (two or more organs) relative to controls, with further adjustments for potential confounders. The C-MORE study is ongoing and is registered with ClinicalTrials.gov, NCT04510025. Findings: Of 2710 participants in Tier 2 of PHOSP-COVID, 531 were recruited across 13 UK-wide C-MORE sites. After exclusions, 259 C-MORE patients (mean age 57 years [SD 12]; 158 [61%] male and 101 [39%] female) who were discharged from hospital with PCR-confirmed or clinically diagnosed COVID-19 between March 1, 2020, and Nov 1, 2021, and 52 non-COVID-19 controls from the community (mean age 49 years [SD 14]; 30 [58%] male and 22 [42%] female) were included in the analysis. Patients were assessed at a median of 5·0 months (IQR 4·2–6·3) after hospital discharge. Compared with non-COVID-19 controls, patients were older, living with more obesity, and had more comorbidities. Multiorgan abnormalities on MRI were more frequent in patients than in controls (157 [61%] of 259 vs 14 [27%] of 52; p<0·0001) and independently associated with COVID-19 status (odds ratio [OR] 2·9 [95% CI 1·5–5·8]; padjusted=0·0023) after adjusting for relevant confounders. Compared with controls, patients were more likely to have MRI evidence of lung abnormalities (p=0·0001; parenchymal abnormalities), brain abnormalities (p<0·0001; more white matter hyperintensities and regional brain volume reduction), and kidney abnormalities (p=0·014; lower medullary T1 and loss of corticomedullary differentiation), whereas cardiac and liver MRI abnormalities were similar between patients and controls. Patients with multiorgan abnormalities were older (difference in mean age 7 years [95% CI 4–10]; mean age of 59·8 years [SD 11·7] with multiorgan abnormalities vs mean age of 52·8 years [11·9] without multiorgan abnormalities; p<0·0001), more likely to have three or more comorbidities (OR 2·47 [1·32–4·82]; padjusted=0·0059), and more likely to have a more severe acute infection (acute CRP >5mg/L, OR 3·55 [1·23–11·88]; padjusted=0·025) than those without multiorgan abnormalities. Presence of lung MRI abnormalities was associated with a two-fold higher risk of chest tightness, and multiorgan MRI abnormalities were associated with severe and very severe persistent physical and mental health impairment (PHOSP-COVID symptom clusters) after hospitalisation. Interpretation: After hospitalisation for COVID-19, people are at risk of multiorgan abnormalities in the medium term. Our findings emphasise the need for proactive multidisciplinary care pathways, with the potential for imaging to guide surveillance frequency and therapeutic stratification

The Calvin Lab : bio-organic chemistry group at the University of California, Berkeley, 1945-1963 /

0

Mean effect across BMI strata of allelic substitutions at representative variants displaying genome-wide significant association with SU in at least one BMI stratum and displaying nominally significant difference in effect size across BMI strata.

<p>Effect size is on standardised age-adjusted SU levels. Error bars indicate the standard errors of the mean effect estimates within a BMI category. Horizontal lines indicate nominally significant (p &lt; 0.05) differences in mean effect sizes between BMI categories, ** indicates significance at the 1% level taking into account the multiple comparisons performed. Differences in mean effect sizes between BMI strata were tested pairwise using the classical z-test, and P_diff denotes the 2-sided test corresponding P-value. Lean: BMI &lt; 25 kg/m², overweight: 25 ≤ BMI ≤ 30 kg/m², obese: BMI &gt; 30 kg/m².</p